Genzyme has appointed Scott Canute as president of global manufacturing and corporate operations. Canute’s appointment, and the addition of Ron Branning last month, is part of Genzyme’s efforts to strengthen its manufacturing operations in response to recent difficulties.
Before joining Genzyme Canute spent 25 years at Eli Lilly, culminating in his appointment as president of global manufacturing operations. He left Lilly in 2007 to pursue interests in business leadership and ethics.
Ted Love has been appointed as executive vice president (EVP) and head of research and development at Onyx Pharmaceuticals. Love was previously CEO of Nuvelo and has also worked at Theravance and Genentech.
In addition Michael Kauffman has been appointed as chief medical officer. Kauffman has been interim chief medical officer at Onyx since November 2009. Before this he worked at Proteolix, EPIX Pharmaceuticals and Biogen.
CPEX Pharmaceuticals has appointed Nils Bergenhem as chief scientific officer (CSO). Bergenhem was previously CSO at Escoublac, the first biotech in the Biogen Idec Innovations Incubator, and has also worked at Adipogenix, OSI Pharmaceuticals and Novo Nordisk.
Odysseas Kostas has joined the board of directors at Adventrex Pharmaceuticals. Kostas was appointed as Carl Icahn’s representative on the board.
Samil Pharmaceuticals has appointed Villur Sundararajan Ram as its CEO. Indian-born Ram is the first non-Korean national to become CEO of a Korean pharma company, according to Samil.
Per Wold-Olsen has joined the board of directors at Gilead Sciences. Wold-Olsen spent 30 years at Merck & Co, most recently serving as president of the company’s Human Health Intercontinental Division.
He also serves on the boards of directors at Lundbeck, GN Store Nord and Exiqon.